MA53543A - Vaccins peptidiques - Google Patents
Vaccins peptidiquesInfo
- Publication number
- MA53543A MA53543A MA053543A MA53543A MA53543A MA 53543 A MA53543 A MA 53543A MA 053543 A MA053543 A MA 053543A MA 53543 A MA53543 A MA 53543A MA 53543 A MA53543 A MA 53543A
- Authority
- MA
- Morocco
- Prior art keywords
- peptide vaccines
- vaccines
- peptide
- Prior art date
Links
- 229940023041 peptide vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1814367.7A GB201814367D0 (en) | 2018-09-04 | 2018-09-04 | Peptide Vaccines |
GBGB1814365.1A GB201814365D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
GBGB1814366.9A GB201814366D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
GBGB1814364.4A GB201814364D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53543A true MA53543A (fr) | 2021-07-14 |
Family
ID=67874441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053543A MA53543A (fr) | 2018-09-04 | 2019-09-03 | Vaccins peptidiques |
Country Status (15)
Country | Link |
---|---|
US (2) | US11666644B2 (fr) |
EP (1) | EP3846845A1 (fr) |
JP (2) | JP2021536487A (fr) |
KR (1) | KR20210086612A (fr) |
CN (1) | CN113329761A (fr) |
AU (1) | AU2019334437A1 (fr) |
BR (1) | BR112021004071A2 (fr) |
CA (1) | CA3110760A1 (fr) |
CL (1) | CL2021000532A1 (fr) |
CO (1) | CO2021004019A2 (fr) |
IL (1) | IL281224A (fr) |
MA (1) | MA53543A (fr) |
MX (1) | MX2021002449A (fr) |
SG (1) | SG11202101888YA (fr) |
WO (1) | WO2020048990A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110651189A (zh) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 肽疫苗 |
MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
JP2024518378A (ja) | 2021-05-05 | 2024-05-01 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Prameに特異的に結合する抗原結合タンパク質 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
BR9708161A (pt) | 1996-03-11 | 1999-07-27 | Epimmune Inc | Peptídeos com aumentada afinidade de ligação para moléculas hla |
US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
EP0970126B1 (fr) | 1997-04-14 | 2001-04-18 | Micromet AG | Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
CA2323514A1 (fr) | 1998-04-01 | 1999-10-07 | Yale University | Methode de modulation selective des interactions entre survivine et tubuline |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
EP1235841A4 (fr) * | 1999-12-10 | 2006-04-12 | Epimmune Inc | Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
CN1691964A (zh) | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
WO2005049073A2 (fr) | 2003-11-19 | 2005-06-02 | Survac Aps | Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer |
CN101434647A (zh) | 2004-01-20 | 2009-05-20 | 爱知县 | 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用 |
WO2005118626A2 (fr) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c |
US20080206270A1 (en) | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
US8487076B1 (en) | 2005-01-25 | 2013-07-16 | Nec Corporation | HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide |
CN103169958A (zh) | 2005-02-04 | 2013-06-26 | 萨瓦克公司 | 存活蛋白肽疫苗 |
CN100402554C (zh) | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
CN101437542A (zh) | 2006-03-01 | 2009-05-20 | 詹森药业有限公司 | 联合淋巴细胞清除剂与ctl及细胞因子的癌症治疗 |
WO2008035350A1 (fr) * | 2006-09-21 | 2008-03-27 | Vaxil Biotherapeutics Ltd. | Vaccins à multiples épitopes spécifiques à un antigène |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
US8124408B2 (en) | 2006-10-04 | 2012-02-28 | Janssen Pharmaceutica N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
US8309096B2 (en) * | 2007-01-15 | 2012-11-13 | Glaxosmithkline Biologicals S.A. | Fusion protein |
EP2361930A3 (fr) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia |
EP2042600A1 (fr) | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications |
CN101981187A (zh) | 2008-03-31 | 2011-02-23 | 株式会社生物免疫平衡 | MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法 |
DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
EP2337795A2 (fr) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
US20120244145A1 (en) | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
US20170039314A1 (en) | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2012051282A2 (fr) | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l) |
WO2012126118A1 (fr) | 2011-03-21 | 2012-09-27 | Atlantic Cancer Research Institute | Polypeptides présentant une affinité pour les protéines de choc thermique (hsp) et complexes associés à une hsp (hacs) et leur utilisation en diagnostic et en thérapie |
WO2014127296A1 (fr) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Vaccins contre le cancer et méthodes de vaccination |
US20140234350A1 (en) | 2013-02-14 | 2014-08-21 | Cedars-Sinai Medical Center | Ovarian cancer vaccines and vaccination methods |
CN111905099A (zh) | 2013-03-27 | 2020-11-10 | 免疫疫苗技术有限公司 | 用于改善存活蛋白疫苗在癌症治疗中的功效的方法 |
WO2014180490A1 (fr) | 2013-05-10 | 2014-11-13 | Biontech Ag | Prédiction de l'immunogénicité d'épitopes de lymphocytes t |
GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
WO2015143335A1 (fr) | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Méthodes et compositions pour protéines spike de coronavirus chimère |
EP3134104B1 (fr) | 2014-04-25 | 2018-12-26 | Tria Bioscience Corp. | Compositions de support d'haptène synthétique et procédés |
CA2961179A1 (fr) | 2014-09-14 | 2016-03-17 | Washington University | Vaccins anticancereux personnalises, et procedes correspondants |
US20160074489A1 (en) | 2014-09-15 | 2016-03-17 | Regen Biopharma, Inc | Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation |
WO2016090177A1 (fr) * | 2014-12-03 | 2016-06-09 | Verik Bio, Inc. | Identification, sélection et utilisation d'épitopes de cellule t à haut potentiel curatif |
EP3242883A4 (fr) | 2015-01-06 | 2018-10-17 | ImmunoVaccine Technologies Inc. | Mimétiques de lipide a, procédés de préparation, et leurs utilisations |
JP7236216B2 (ja) | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
US20180162913A1 (en) | 2015-05-01 | 2018-06-14 | Immunovaccine Technologies Inc. | Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines |
US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
US11191820B2 (en) * | 2015-06-29 | 2021-12-07 | Ose Immunotherapeutics | Method for inducing early T memory response with short peptides anti-tumor vaccine |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
US9790562B2 (en) | 2015-09-30 | 2017-10-17 | Augusta University Research Institute, Inc. | Compositions and methods for the detection or treatment of uterine leiomyosarcoma |
JP2018532736A (ja) | 2015-10-12 | 2018-11-08 | ナントミクス,エルエルシー | チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法 |
CN105219723A (zh) * | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活胃癌特异性免疫反应的试剂盒 |
WO2017083963A1 (fr) | 2015-11-18 | 2017-05-26 | Immunovaccine Technologies Inc. | Systèmes adjuvant et compositions vaccinales sans eau comprenant un adjuvant de type polyi:c et un adjuvant lipidique |
GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
CA3023560A1 (fr) | 2016-05-13 | 2017-11-16 | Mbl International Corp. | Systeme et procede d'echange de peptides |
JP2020503840A (ja) * | 2016-10-07 | 2020-02-06 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Hla拘束性vgll1ペプチドおよびその使用 |
WO2018102585A1 (fr) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes |
MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
EP3369431A1 (fr) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccin |
CN110651189A (zh) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 肽疫苗 |
EP3370065A1 (fr) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Peptides immunogènes |
US20200230057A1 (en) | 2017-07-10 | 2020-07-23 | Immunovaccine Technologies Inc. | Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof |
US20210177955A1 (en) | 2017-11-08 | 2021-06-17 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
JP7103726B2 (ja) | 2017-11-09 | 2022-07-20 | イミューノヴァクシーン テクノロジーズ インコーポレイテッド | 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用 |
WO2019133853A1 (fr) * | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Protéines se liant à l'antigène ciblant des antigènes partagés |
US20210213066A1 (en) | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
EP3796923A4 (fr) | 2018-05-18 | 2022-03-09 | Children's National Medical Center | Thérapie ciblée améliorée par lymphocytes t |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
AU2019383785A1 (en) | 2018-11-19 | 2021-06-03 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
WO2020146434A2 (fr) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation |
EP3908292A4 (fr) | 2019-01-07 | 2023-01-04 | Children's National Medical Center | Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple |
CA3153179A1 (fr) | 2019-10-16 | 2021-04-22 | Immunovaccine Technologies Inc. | Formulations d'emulsion a phase continue aqueuse pour l'administration d'agents actifs ou therapeutiques |
CN110713546B (zh) | 2019-10-31 | 2021-04-20 | 中国医科大学附属第一医院 | 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途 |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2019
- 2019-09-03 MA MA053543A patent/MA53543A/fr unknown
- 2019-09-03 CA CA3110760A patent/CA3110760A1/fr active Pending
- 2019-09-03 WO PCT/EP2019/073476 patent/WO2020048990A1/fr active Application Filing
- 2019-09-03 US US17/250,725 patent/US11666644B2/en active Active
- 2019-09-03 JP JP2021512904A patent/JP2021536487A/ja active Pending
- 2019-09-03 BR BR112021004071-4A patent/BR112021004071A2/pt unknown
- 2019-09-03 AU AU2019334437A patent/AU2019334437A1/en active Pending
- 2019-09-03 CN CN201980071002.0A patent/CN113329761A/zh active Pending
- 2019-09-03 KR KR1020217009977A patent/KR20210086612A/ko active Search and Examination
- 2019-09-03 MX MX2021002449A patent/MX2021002449A/es unknown
- 2019-09-03 SG SG11202101888YA patent/SG11202101888YA/en unknown
- 2019-09-03 EP EP19765218.3A patent/EP3846845A1/fr active Pending
-
2021
- 2021-03-03 IL IL281224A patent/IL281224A/en unknown
- 2021-03-04 CL CL2021000532A patent/CL2021000532A1/es unknown
- 2021-03-30 CO CONC2021/0004019A patent/CO2021004019A2/es unknown
-
2023
- 2023-05-02 US US18/311,117 patent/US20240000911A1/en active Pending
-
2024
- 2024-04-23 JP JP2024070125A patent/JP2024097033A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2021000532A1 (es) | 2021-09-24 |
CO2021004019A2 (es) | 2021-07-19 |
JP2021536487A (ja) | 2021-12-27 |
JP2024097033A (ja) | 2024-07-17 |
US20230102031A1 (en) | 2023-03-30 |
IL281224A (en) | 2021-04-29 |
WO2020048990A1 (fr) | 2020-03-12 |
US11666644B2 (en) | 2023-06-06 |
SG11202101888YA (en) | 2021-03-30 |
KR20210086612A (ko) | 2021-07-08 |
EP3846845A1 (fr) | 2021-07-14 |
CA3110760A1 (fr) | 2020-03-12 |
CN113329761A (zh) | 2021-08-31 |
US20240000911A1 (en) | 2024-01-04 |
BR112021004071A2 (pt) | 2021-06-01 |
MX2021002449A (es) | 2021-08-05 |
AU2019334437A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47677A (fr) | Vaccins peptidiques | |
MA46766A (fr) | Vaccin antigrippal | |
MA46584A (fr) | Vaccin contre le cytomégalovirus humain | |
DK3393505T3 (da) | Rekombinante zika-vacciner | |
DK3393510T3 (da) | Zikavirusvaccine | |
DK3463465T3 (da) | Exosomer omfattende terapeutiske polypeptider | |
MA46255A (fr) | Vaccins anticancéreux | |
MA46316A (fr) | Vaccin contre le cytomégalovirus humain | |
DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
MA46378A (fr) | Vaccins hpv16 thérapeutiques | |
DK3558351T3 (da) | Kombinationsvaccine til svin | |
DK3548058T3 (da) | Sammensætninger omfattende peptid wkdeagkplvk | |
MA52011A (fr) | Vaccins peptidiques contre l'interleukine-31 | |
DK3840767T3 (da) | Peptider | |
IL281224A (en) | Peptide compounds | |
DK3244920T3 (da) | Mund- og klovsyge-vaccine | |
DK3274447T3 (da) | Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine | |
DK3590523T3 (da) | Vækstfremmende peptider og anvendelser deraf | |
IL278830A (en) | Reverse peptide vaccine | |
DK3512544T3 (da) | Peptidforbindelser og terapeutiske anvendelser deraf | |
MA52180A (fr) | Vaccins thérapeutiques anti-abêta | |
DK3178838T3 (da) | Koc1-afledt peptid og vaccine, der indbefatter dette | |
DK3630793T3 (da) | Rekombinant protein | |
DK3405212T3 (da) | Cancervacciner | |
MA52588A (fr) | Macrocyclase peptidique |